ESR1 and breast carcinoma: Their results suggested that the combination of two drugs upholds mTORC1 suppression while impeding Akt activation and autophagy increase, which resulted in apoptosis of ER+ (MCF7) and ER- (MDA-MB-231) breast cancer cells (123).